Holen Sie sich die Stockscreener-App
3.08
37.50%
0.84
Schlusskurs vom Vortag:
$2.24
Offen:
$2.37
24-Stunden-Volumen:
2.46M
Relative Volume:
3.60
Marktkapitalisierung:
$446.52M
Einnahmen:
$28.94M
Nettoeinkommen (Verlust:
$-54.29M
KGV:
-6.6279
EPS:
-0.4647
Netto-Cashflow:
$-26.02M
1W Leistung:
+55.56%
1M Leistung:
+32.76%
6M Leistung:
+81.18%
1J Leistung:
+63.83%
1-Tages-Spanne:
$2.352
$3.12
1-Wochen-Bereich:
$1.94
$3.12
52-Wochen-Spanne:
$1.30
$3.12
Omniab Inc Stock (OABI) Company Profile
Firmenname
Omniab Inc
Sektor
Branche
Telefon
510-250-7800
Adresse
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
3.08 | 294.29M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-21 | Eingeleitet | The Benchmark Company | Buy |
| 2023-04-13 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-22 | Eingeleitet | Cowen | Outperform |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-29 | Eingeleitet | SVB Leerink | Outperform |
| 2022-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Omniab Inc Aktie (OABI) Neueste Nachrichten
Enterprise value to EBIT forward of OmniAb, Inc. – NASDAQ:OABI - TradingView
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com South Africa
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - Benzinga
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
OmniAb Inc (OABI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
OABI|OmniAb Inc|Price:2.000|Chg%:-0.030 - TradingKey
Veraxa advances cancer therapy program with OmniAb - Investing.com
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan
OmniAb Inc (OABI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OmniAb Inc (OABI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OABI|OmniAb Inc|Price:1.955|Chg%:-0.075 - TradingKey
TradingKey - TradingKey
OmniAb Inc (OABI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OmniAb Market Sentiment - Benzinga
OmniAb Inc (OABI) Balance Sheet - TradingKey
OABI|OmniAb Inc|Price:2.030| - TradingKey
Price to sales forward of OmniAb, Inc. – NASDAQ:OABI - TradingView
OmniAb Inc (OABI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OmniAb (OABI) Holds Near Support Amid Modest DeclineFear Greed Extreme - dars.gov.et
OmniAb spotlights OmniUltra platform for radioligand therapy at San Diego summit - Traders Union
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OABI|OmniAb Inc|Price:2.030|Chg%:-0.010 - TradingKey
OmniAb to present in vivo discovery technology for radioligand therapy at San Diego summit - Traders Union
Enterprise value to EBITDA forward of OmniAb, Inc. – NASDAQ:OABI - TradingView
OmniAb Q1 2026 Earnings: EPS Surprises Positively Despite Pre-Revenue StageAnalyst Earnings Estimate - dars.gov.et
OmniAb to Report Second Quarter 2026 Financial Results on August 6 - BioSpace
OmniAb stock rises after naming new chief operating officer - Investing.com
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer Effective July 13, 2026 - geneonline.com
OmniAb, Inc. Appoints Amechi Nwachuku as Chief Operating Officer – Leadership Update July 2026 - Minichart
OmniAb appoints Amechi Nwachuku as chief operating officer - Investing.com UK
OMEGA relocates headquarters from Cambridge to New Philadelphia - AOL.com
Omniab, Inc. Appoints Amechi Nwachuku as Executive Vice President and Chief Operating Officer, Effective July 13, 2026 - marketscreener.com
OmniAb Taps Amechi Nwachuku as Executive Vice President & Chief Operating Officer - Contract Pharma
OmniAb stock rises after naming new chief operating officer By Investing.com - Investing.com Nigeria
OmniAb Appoints Amechi Nwachuku COO to Expand xPloration Platform Commercialization - citybiz
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer - Moomoo
OmniAb appoints Amechi Nwachuku as chief operating officer By Investing.com - Investing.com South Africa
OmniAb Names Amechi Nwachuku Chief Operating Officer - TipRanks
Amechi Nwachuku named COO at OmniAb with stock options and severance - TradingView
OmniAb (NASDAQ: OABI) hires COO with $445K salary, 800K options - Stock Titan
OmniAb Inc. (OABI) Climbs 2.23% as Shares Approach Key Resistance at $2.40Strangle Setup - dars.gov.et
OmniAb (OABI) Edges Lower Amid Quiet Trading – Support Levels in FocusLow Volume Node - dars.gov.et
OABI,VKTX Revenue Breakdown - Finviz
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - GlobeNewswire Inc.
OmniAb Inc. (OABI) Edges Higher, Testing Key Resistance ZoneMomentum Breakout Ideas - dars.gov.et
OmniAb (OABI) Price Target Decreased by 13.73% to 7.48 - MSN
OABIOmniAb Inc Volatility & Greeks - Finviz
Finanzdaten der Omniab Inc-Aktie (OABI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Omniab Inc-Aktie (OABI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):